AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 3, 2001
FILE NO. 333-
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------------------
STEMCELLS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 94-3078125
(State or Other Jurisdiction (I.R.S. Employer
of Incorporation or Identification No.)
Organization)
3155 PORTER DRIVE
PALO ALTO, CA 94304
(650) 475-3100
(Address of Principal Executive Offices)
------------------------
2001 EQUITY INCENTIVE PLAN
(Full Title of the Plans)
IRIS BREST, ESQ.
STEMCELLS, INC.
3155 PORTER DRIVE
PALO ALTO, CA 94304
(605) 475-3100
(Name, Address and Telephone Number, including Area Code, of Agent for Service)
------------------------
CALCULATION OF REGISTRATION FEE
TITLE OF SECURITIES AMOUNT PROPOSED MAXIMUM PROPOSED MAXIMUM AMOUNT OF
TO BE TO BE OFFERING PRICE PER AGGREGATE OFFERING REGISTRATION
REGISTERED REGISTERED SHARE(1) PRICE(2) FEE
Common Stock,
Par Value $0.01.................. 3,000,000 shares $3.10-$4.275 $12,768,304 $3,192
(1) The offering price for shares subject to options on the date hereof is the
actual exercise price of such options. Of the 3,000,000 shares to be
registered hereunder, 74,500 are subject to options at an exercise price of
$3.10 per share and 82,249 are subject to options at an exercise price of
$4.65 per share. The offering price for the remaining 2,843,251 shares not
subject to options on the date hereof of $4.275 per share has been estimated
solely for the purpose of determining the registration fee pursuant to
Rule 457(h) on the basis of the average of the high and low prices of
StemCells, Inc., Common Stock, par value $0.01 per share, reported on the
Nasdaq National Market on August 2, 2001.
(2) The maximum aggregate offering price consists of $230,950 payable in respect
of 74,500 shares subject to options at an exercise price of $3.10 per share,
$382,456 payable in respect of 82,249 shares subject to options at an
exercise price of $4.65 per share, plus $12,154,898 payable in respect of
2,843,251 shares not subject to options on the date hereof.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
StemCells, Inc., (the "Registrant" or the "Company") hereby incorporates the
following documents herein by reference:
(a) The Registrant's latest Annual Report on Form 10-K for the year ended
December 31, 2000, as filed with the Securities and Exchange Commission
(the "Commission") pursuant to Section 13 under the Exchange Act of 1934
(the "Exchange Act"), on April 2, 2001, and as amended on April 30, 2001.
(b) Quarterly Report on Form 10-Q for the quarter ended March 31, 2001, as
filed with the Commission pursuant to Section 13 under the Exchange Act
on May 8, 2001. Current Report on Form 8-K, as filed with the Commission
pursuant to Section 13 of the Exchange Act on May 14, 2001; Current
Report on Form 8-K, as filed with the Commission pursuant to Section 13
of the Exchange Act on May 8, 2001.
(c) The description of the common stock of the Registrant contained in the
Registrant's Registration Statement on Form 8-A (File No. 1-19871),
including all amendments and reports filed for the purpose of updating
such description.
All documents subsequently filed by the Registrant pursuant to
Section 13(a), Section 13(c), Section 14 and Section 15(d) of the Exchange Act,
prior to the filing of a post-effective amendment to this Registration Statement
that indicates that all securities offered have been sold or which de-registers
all securities then remaining unsold, shall be deemed to be incorporated herein
by reference from the date of filing of such documents.
ITEM 4. DESCRIPTION OF SECURITIES.
Not applicable.
ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.
Not applicable.
ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Section 145 of the Delaware General Corporation Law provides that a
corporation may indemnify any person who was or is a party or is threatened to
be made a party to any threatened, pending or completed action, suit or
proceeding, whether civil, criminal, administrative or investigative, other than
an action by or in the right of the corporation, by reason of the fact that the
person is or was a director, officer, employee or agent of the corporation or is
or was serving at the corporation's request as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust or other
enterprise, against expenses, including attorneys' fees, judgments, fines and
amounts paid in settlement actually and reasonably incurred by the person in
connection with the action, suit or proceeding if the person acted in good faith
and in a manner the person reasonably believed to be in or not opposed to the
best interests of the corporation, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe the person's conduct was
unlawful. The power to indemnify applies to actions brought by or in the right
of the corporation as well, but only to the extent of expenses, including
attorneys' fees but excluding judgments, fines and amounts paid in settlement,
actually and reasonably incurred by the person in connection with the defense or
settlement of the action or suit and with the further limitation that in these
actions no indemnification shall be made in
II-1
the event of any adjudication of negligence or misconduct in the performance of
his duties to the corporation, unless a court believes that in light of all the
circumstances indemnification should apply.
Section Ten of our Restated Certificate of Incorporation provides that we
shall, to the maximum extent legally permitted, indemnify and upon request
advance expenses to each person who is or was a party or is threatened to be
made a party to any threatened, pending or completed action, suit proceeding, or
claim (civil, criminal, administrative or investigative) by reason of the fact
that he is or was, or has agreed to become, a director or officer of the
Company, or is or was serving, or has agreed to serve, at the request of the
Company, as a director, officer, partner, employee, agent or trustee of, or in a
similar capacity with, another corporation, partnership, joint venture, trust or
other enterprises, provided, however, that the Company is not required to
indemnify or advance expenses to any person in connection with any action, suit,
proceeding, claim or counterclaim initiated by or on behalf of such person. The
indemnification provided for in Section Ten is expressly not exclusive of any
other rights to which those seeking indemnification may be entitled under any
by-law, agreement or vote of directors or stockholders or otherwise, and shall
inure to the benefit of the heirs and legal representatives of such persons.
Section 145(g) of the Delaware General Corporation Law provides that the
Company shall have the power to purchase and maintain insurance on behalf of its
officers, directors, employees and agents, against any liability asserted
against and incurred by such persons in any such capacity.
We have obtained insurance covering our directors and officers against
certain liabilities.
Section 102(b)(7) of the General Corporation Law of the State of Delaware
provides that a corporation may eliminate or limit the personal liability of a
director to the corporation or its stockholders for monetary damages for breach
of fiduciary duty as a director, provided that such provisions shall not
eliminate or limit the liability of a director (i) for any breach of the
director's duty of loyalty to the corporation or its stockholders, (ii) for acts
or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii) under Section 174 of the General Corporation Law
of the State of Delaware, or (iv) for any transaction from which the director
derived an improper personal benefit. No such provision shall eliminate or limit
the liability of a director for any act or omission occurring prior to the date
when such provision becomes effective.
Pursuant to the Delaware General Corporation Law, Section Nine of the
Company's Restated Certificate of Incorporation eliminates a director's personal
liability for monetary damages for breach of fiduciary duty as a director,
except in circumstances involving a breach of the director's duty of loyalty to
StemCells, Inc. or its shareholders, acts or omissions not in good faith,
intentional misconduct, knowing violations of the law, self-dealing or the
unlawful payment of dividends or repurchase of stock.
ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED.
Not applicable.
ITEM 8. EXHIBITS.
EXHIBIT
- ---------------------
4.1 2001 Equity Incentive Plan (Previously filed as Annex A to
the Proxy Statement filed with the Commission, pursuant to
Section 14(a) of the Exchange Act, on April 30, 2001).
5.1 Opinion of Ropes & Gray.
23.1. Consent of Ropes & Gray (See Exhibit 5).
23.2. Consent of Ernst & Young LLP, Independent Auditors.
24. Power of Attorney (Included on Signature Page).
II-2
ITEM 9. UNDERTAKINGS.
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the
effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set
forth in the Registration Statement;
(iii) To include any material information with respect to the plan of
distribution not previously disclosed in the Registration Statement
or any material change to such information in this Registration
Statement;
PROVIDED, HOWEVER, that paragraphs (a)(1)(i) and (a)(1)(ii) above shall
not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in periodic reports filed with
or furnished to the Securities and Exchange Commission by the Registrant
pursuant to Section 13 or Section 15(d) of the Exchange Act that are
incorporated by reference in this Registration Statement.
(2) That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the
termination of the offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of
the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of
the Securities Exchange Act of 1934 that is incorporated by reference in the
Registration Statement shall be deemed to be a new Registration Statement
relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering
thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to directors, officers and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise, the
Registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a
claim for indemnification against such liabilities (other than the payment
by the Registrant of expenses incurred or paid by a director, officer or
controlling person of the Registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration
Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto
duly authorized, in Palo Alto, California on this the 3d day of August, 2001.
STEMCELLS, INC.
By: /s/ MARTIN M. MCGLYNN
-----------------------------------------
Martin M. McGlynn
DIRECTOR, PRESIDENT AND
CHIEF EXECUTIVE OFFICER
Each person whose signature appears below constitutes and appoints Martin M.
McGlynn and Iris Brest, and each of them singly, his true and lawful
attorney-in-fact and agent with full power of substitution and re-substitution,
for him and in his name, place and stead, in any and all capacities, to sign any
and all amendments (including post-effective amendments) to this Registration
Statement on Form S-8 to be filed by StemCells, Inc., and to file the same, with
all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and
agents full power and authority to be done in and about the premises, as fully
to all intents and purposes as he or she might or could do in person, hereby
ratifying and confirming all that said attorneys-in-fact and agents, or their
substitutes, may lawfully do or cause to be done by virtue hereof.
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THIS
REGISTRATION STATEMENT HAS BEEN SIGNED BY THE FOLLOWING PERSONS IN THE
CAPACITIES AND ON THE DATES INDICATED.
SIGNATURES TITLE DATE
---------- ----- ----
/s/ MARTIN M. MCGLYNN
------------------------------------------- Director, President and August 3, 2001
Martin M. McGlynn Chief Executive Officer
Controller and Acting Chief
Financial Officer
/s/ GEORGE KOSHY (Principal
------------------------------------------- Financial Officer and August 3, 2001
George Koshy Principal Accounting
Officer)
/s/ MARK J. LEVIN
------------------------------------------- Director August 3, 2001
Mark J. Levin
/s/ ROGER M. PERLMUTTER
------------------------------------------- Director August 3, 2001
Roger M. Perlmutter M.D., Ph.D.
/s/ JOHN J. SCHWARTZ
------------------------------------------- Director August 3, 2001
John J. Schwartz, Ph.D.
------------------------------------------- Director August 3, 2001
Irving L. Weissman, M.D.
EXHIBIT INDEX
EXHIBIT
NUMBER TITLE OF EXHIBIT
- --------------------- ------------------------------------------------------------
4.1 2001 Equity Incentive Plan (Previously filed as Annex A to
the Proxy Statement filed with the Commission, pursuant to
Section 14(a) of the Exchange Act, on April 30, 2001).
5.1 Opinion of Ropes & Gray.
23.1. Consent of Ropes & Gray (See Exhibit 5.1).
23.2. Consent of Ernst & Young LLP, Independent Auditors.
24. Power of Attorney (Included on Signature Page).
EXHIBIT 5.1
August 3, 2001
StemCells, Inc.
3155 Porter Drive
Palo Alto, CA 94304
Ladies and Gentlemen:
This opinion is furnished to you in connection with a registration statement
on Form S-8 (the "Registration Statement"), filed with the Securities and
Exchange Commission under the Securities Act of 1933, as amended, on or about
the date hereof for the registration of 3,000,000 shares of Common Stock, $.01
par value (the "Shares"), of StemCells, Inc., a Delaware corporation (the
"Company"). The Shares are issuable under the Company's 2001 Equity Incentive
Plan (the "Plan").
We are familiar with the actions taken by the Company in connection with the
Plan. For purposes of our opinion, we have examined and relied upon such
documents, records, certificates and other instruments as we have deemed
necessary.
Based on the foregoing, we are of the opinion that, when the Shares have
been issued and sold and consideration received therefor by the Company in
accordance with the terms of the Plan, the Shares will be validly issued, fully
paid and non-assessable.
We hereby consent to your filing of this opinion as an exhibit to the
Registration Statement.
It is understood that this opinion is to be used only in connection with the
offer and sale of Shares while the Registration Statement is in effect.
Very truly yours,
/s/ Ropes & Gray
Ropes & Gray
EXHIBIT 23.2
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the incorporation by reference in this Registration Statement
on Form S-8, pertaining to the StemCells, Inc., 2001 Equity Incentive Plan, of
our report dated February 23, 2001 with respect to the consolidated financial
statements of StemCells, Inc., included in its Annual Report on Form 10-K/A for
the year ended December 31, 2000 filed with the Securities and Exchange
Commission.
Ernst & Young LLP
Palo Alto, California
August 2, 2001
